A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV)

MLA

Prabhat K Agarwal, et al. “A Prospective, Multicentre Study Evaluating Safety and Efficacy of a Fixed Dose Combination of Remogliflozin Etabonate, Vildagliptin, and Metformin in Indian Patients with Type 2 Diabetes Mellitus (Triad-RMV).” Clinical Diabetes and Endocrinology, vol. 10, no. 1, Dec. 2024, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s40842-024-00210-8.

APA

Prabhat K Agarwal, Divendu Bhushan, Amit Bhate, Sunil Naik, Shailesh Adwani, J S Kushwaha, Sumit Bhushan, Abhishek Mane, Rujuta Gadkari, Sanjay Choudhari, Saiprasad Patil, & Hanmant Barkate. (2024). A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV). Clinical Diabetes and Endocrinology, 10(1), 1–9. https://doi.org/10.1186/s40842-024-00210-8

Chicago

Prabhat K Agarwal, Divendu Bhushan, Amit Bhate, Sunil Naik, Shailesh Adwani, J S Kushwaha, Sumit Bhushan, et al. 2024. “A Prospective, Multicentre Study Evaluating Safety and Efficacy of a Fixed Dose Combination of Remogliflozin Etabonate, Vildagliptin, and Metformin in Indian Patients with Type 2 Diabetes Mellitus (Triad-RMV).” Clinical Diabetes and Endocrinology 10 (1): 1–9. doi:10.1186/s40842-024-00210-8.